Articles

Collaboration combats cystic fibrosis

Forest acquires rights from Germany’s Grunenthal for CF treatment, prevention
Written byLori Lesko
| 2 min read

AACHEN, Germany—In the second strategic collaboration forgedin December between family-owned drugmaker The Grunenthal Group, and NewYork-headquartered biotech Forest Laboratories Inc., Forest acquired all rightscurrently held by Grunenthal for colistin and all rights previously licensed byForest to Grunenthal for colobreathe.

Both are treatments for cystic fibrosis(CF), an inherited disease with no cure.

Grunenthal divested the colistin franchise as part of itsstrategy to focus its business on its core pain franchise. Financial details ofthe agreement were not disclosed, according to the Dec. 20 joint announcement.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of a multicolored protein structure composed of folded ribbon-like strands against a blue and teal background with scattered spherical particles
Learn how advanced analytical methods support the characterization of antibody–C1q interactions and the qualification of analytical binding assays.